Quang Pham Sells 881 Shares of Cadrenal Therapeutics (NASDAQ:CVKD) Stock

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) CEO Quang Pham sold 881 shares of the firm’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $14.01, for a total value of $12,342.81. Following the sale, the chief executive officer owned 202,633 shares of the company’s stock, valued at approximately $2,838,888.33. This trade represents a 0.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Cadrenal Therapeutics Stock Up 1.7%

Shares of NASDAQ CVKD opened at $14.06 on Thursday. Cadrenal Therapeutics, Inc. has a fifty-two week low of $8.74 and a fifty-two week high of $22.90. The business has a 50 day moving average price of $12.50 and a two-hundred day moving average price of $14.04. The firm has a market cap of $28.82 million, a PE ratio of -1.58 and a beta of 0.96.

Cadrenal Therapeutics (NASDAQ:CVKD) last issued its quarterly earnings data on Monday, August 11th. The company reported ($1.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.27). On average, analysts anticipate that Cadrenal Therapeutics, Inc. will post -7.59 earnings per share for the current year.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.